Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -30265.74%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-30265.74%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$669.04M
EBITDA Margin
18.82%
TTM Avg
18.71%
3Y Avg
11.51%
5Y Avg
4.96%
Market Cap
$680.29M
EBITDA Margin
-1285.45%
TTM Avg
-897.10%
3Y Avg
-897.10%
5Y Avg
-897.10%
Market Cap
$661.98M
EBITDA Margin
-178.29%
TTM Avg
-244867.52%
3Y Avg
-123424.79%
5Y Avg
-82415.31%
Market Cap
$656.89M
EBITDA Margin
-5.80%
TTM Avg
-5.80%
3Y Avg
-5.80%
5Y Avg
-5.80%
Market Cap
$695.21M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
Market Cap
$700.53M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$705.43M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $672.79M | -30265.74% | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $669.30M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $669.04M | 18.82% | 18.71% | 11.51% | 4.96% |
| Solid Biosciences Inc. (SLDB)vs › | $680.29M | -1285.45% | -897.10% | -897.10% | -897.10% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $661.98M | -178.29% | -244867.52% | -123424.79% | -82415.31% |
| Starling Oncology, Inc. (STLN)vs › | $656.89M | -5.80% | -5.80% | -5.80% | -5.80% |
| Anteris Technologies Global Corp. (AVR)vs › | $695.21M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $700.53M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $705.43M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| OmniAb, Inc. (OABI)vs › | $640.78M | -266.60% | -229.77% | -154.97% | -121.91% |
Gross Margin
100.3%
EBITDA Margin
-30265.7%
Operating Margin
317.1%
Net Margin
329.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-06-30 | -488.43% |
